
Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from Georgetown University.
2395 articles by Ned Pagliarulo
-
Pricey new gene therapies for sickle cell pose access test
Dec. 8, 2023 -
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
Dec. 8, 2023 -
AbbVie to buy Cerevel in $8.7B bet on brain drugs
Dec. 6, 2023 -
Novartis gets FDA approval of closely watched rare disease drug
Dec. 6, 2023 -
J&J pitches investors on sales growth from cancer, immune disease drugs
Dec. 5, 2023 -
EyePoint sees stock surge on AMD drug trial data
Dec. 4, 2023 -
Pfizer plans for oral obesity drug hit new setback
Dec. 1, 2023 -
Novartis sees brighter sales future as R&D revamp continues
Nov. 28, 2023 -
Regeneron, Sanofi to seek new Dupixent approval in US after COPD success
Nov. 27, 2023 -
Freeline, after cuts, agrees to take-private deal with Syncona
Nov. 22, 2023 -
Bristol Myers faces FDA delay on cancer cell therapy decision
Nov. 20, 2023 -
World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia
Nov. 16, 2023 -
Anthos blood thinner bests Xarelto on safety in mid-stage study
Nov. 13, 2023 -
First look at Verve study data offers base editing ‘proof of principle’
Nov. 12, 2023 -
Novo takes aim at obesity drug shortages with $6B manufacturing plan
Nov. 10, 2023 -
Lilly rival to weight loss drug Wegovy approved by FDA
Nov. 8, 2023 -
What if a CRISPR cure isn’t such an easy choice?
Nov. 8, 2023 -
Biogen, Sage set price of postpartum depression pill at $15,900
Nov. 7, 2023 -
Celldex’s reinvention advances with inflammatory disease drug data
Nov. 6, 2023 -
November brings new flurry of biotech layoffs
Nov. 3, 2023 -
Vertex, CRISPR therapy for sickle cell passes FDA panel test
Oct. 31, 2023 -
A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
Oct. 31, 2023 -
Lilly buys out Beam in heart drug alliance with Verve
Oct. 31, 2023 -
Sarepta gene therapy for Duchenne misses main goal of key study
Oct. 30, 2023 -
Novartis bet on kidney disease drug yields positive study data
Oct. 30, 2023